Rosiglitazone affects lumen formation in MDCKII cell through regulating apico-basal polarity.

This study aimed to investigate the potential mechanisms underlying the effects of Rosiglitazone on the apico-basal polarity in renal epithelial cells. 3D-MDCK model was used to study the lumen formation and localization of polarity proteins at the early stage of the establishment of the apico-basal polarity. The calcium switch model, immunofluorescence staining and measurement of transmembrane electrical impedance are employed to investigate the epithelial apico-basal polarity including the development and maintenance of apical domains and the formation of tight junction. MDCKII cells were cultured with 20 uM rosiglitazone or DMSO. Results showed Rosiglitazone reduced the percentage of single central lumen cysts, but the percentage of multiple lumen cysts increased. At the early stage of MDCKII cysts (2-5 cells), Rosiglitazone induced mislocalization of apical and basolateral membrane proteins. In the repolarization process of MDCKII cell induced by a calcium switch (CS), Rosiglitazone delayed the apical membrane domain development in the early phase of cell polarization; while during the maintenance phase of cell polarity, the apical domain retention was significantly affected by Rosiglitazone. Rosiglitazone significantly delayed the formation of tight junctions (TJs); 24 h after CS, however, there were no apparent differences between control group and Rosiglitazone group; the development of transepithelial electrical resistance (TER) was significantly disturbed in Rosiglitazone group. This study shows Rosiglitazone may affect the development and maintenance of apical domains and the formation of TJs disturbs apical protein delivery to the plasma membrane, eventually leading to the abnormal apico-basal polarity, which affects lumen formation in MDCKII cells.